NanoCarrier Co., Ltd.

Tokyo Stock Exchange 4571.T

NanoCarrier Co., Ltd. Cash and Short-Term Investments for the year ending March 31, 2024: USD 28.26 M

NanoCarrier Co., Ltd. Cash and Short-Term Investments is USD 28.26 M for the year ending March 31, 2024, a -15.50% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

NanoCarrier Co., Ltd. Cash and Short-Term Investments for the year ending March 31, 2023 was USD 33.45 M, a -31.51% change year over year.
NanoCarrier Co., Ltd. Cash and Short-Term Investments for the year ending March 31, 2022 was USD 48.84 M, a -15.52% change year over year.
NanoCarrier Co., Ltd. Cash and Short-Term Investments for the year ending March 31, 2021 was USD 57.81 M, a -16.78% change year over year.
NanoCarrier Co., Ltd. Cash and Short-Term Investments for the year ending March 31, 2020 was USD 69.47 M, a 17.30% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

Tokyo Stock Exchange: 4571.T

NanoCarrier Co., Ltd.

CEO	Dr. Shiro Akinaga Ph.D.
IPO Date	March 5, 2008
Location	Japan
Headquarters	Onoya-Kyobashi Building
Employees	18
Sector	Health Care
Industries Pharmaceuticals Biotechnology Chemicals & Advanced Materials

Description

NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceuticals using micelle nanoparticle technology primarily for the treatment of cancer in Japan. The company's product pipeline includes VB-111 non-proliferative adenovirus vector, which is in phase III clinical trials for the treatment of ovarian cancer, as well as in phase II clinical trials for treatment of rGBM and colorectal cancer; ENT103 Otolaryngology product that is in phase III clinical trials for the treatment of otitis media; NC-6004 Cisplatin micelle, which is in phase II clinical trials for the treatment of head and neck cancer; NC-6300 Epirubicin micelle that is in phase I clinical trials for the treatment of hemangiosarcoma; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma and RUNX1 (mRNA) for osteoarthritis of the knee that are in preclinical stage. The company was founded in 1996 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years